UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

REFERENCES

Alghasham, A.A., 2013. Cucurbitacins : A Promising Target for Cancer Therapy. Int. J. Health Sci. 7, 77–89. https://doi.org/10.12816/0006025

Arteaga, C.L., Engelman, J.A., 2014. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell 25, 282–303. https://doi.org/10.1016/j.ccr.2014.02.025

Awrahman, H.A., Mohamad, D., 2024. Advanced breast cancer diagnosis: Multiplex RT-qPCR for precise typing and angiogenesis profiling. Biochem. Biophys. Rep. 37, 101615. https://doi.org/10.1016/j.bbrep.2023.101615

Benz, C.C., Scott, G.K., Sarup, J.C., Johnson, R.M., Tripathy, D., Coronado, E., Shepard, H.M., Osborne, C.K., 1992. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24, 85–95. https://doi.org/10.1007/BF01961241

Bergholz, J.S., Zhao, J.J., 2021. How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer. Cancer Res. 81, 6074–6077. https://doi.org/10.1158/0008-5472.CAN-21-3605

Birbo, B., Madu, E.E., Madu, C.O., Jain, A., Lu, Y., 2021. Role of HSP90 in Cancer. Int. J. Mol. Sci. 22, 10317. https://doi.org/10.3390/ijms221910317

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J.J., Spratt, D.E., Viola-Villegas, N.T., Castel, P., Minuesa, G., Morse, N., Rodón, J., Ibrahim, Y., Cortes, J., Perez-Garcia, J., Galvan, P., Grueso, J., Guzman, M., Katzenellenbogen, J.A., Kharas, M., Lewis, J.S., Dickler, M., Serra, V., Rosen, N., Chandarlapaty, S., Scaltriti, M., Baselga, J., 2015. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Transl. Med. 7, 283ra51. https://doi.org/10.1126/scitranslmed.aaa4442

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., Jemal, A., 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 74, 229–263. https://doi.org/10.3322/caac.21834

Brouwer, I.J., Out-Luiting, J.J., Vermeer, M.H., Tensen, C.P., 2020. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. Biochem. Biophys. Rep. 24, 100832. https://doi.org/10.1016/j.bbrep.2020.100832

Cao, W., Li, X., Zheng, S., Zheng, W., Wong, Y., Chen, T., 2014. Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk. Oncotarget 5, 7431–7445. https://doi.org/10.18632/oncotarget.2008

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M.-J., Carey, L.A., Cortés, J., Saghir, N.S.E., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S.-B., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., Winer, E.P., 2020. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623–1649. https://doi.org/10.1016/j.annonc.2020.09.010

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., Rosen, N., 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58–71. https://doi.org/10.1016/j.ccr.2010.10.031

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Cheng, Q., Chang, J.T., Geradts, J., Neckers, L.M., Haystead, T., Spector, N.L., Lyerly, H.K., 2012. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. BCR 14, R62. https://doi.org/10.1186/bcr3168

Cheng, X., 2024. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes 15, 903. https://doi.org/10.3390/genes15070903

Chia, S.K., Ellard, S.L., Mates, M., Welch, S., Mihalcioiu, C., Miller, W.H., Gelmon, K., Lohrisch, C., Kumar, V., Taylor, S., Hagerman, L., Goodwin, R., Wang, T., Sakashita, S., Tsao, M.S., Eisenhauer, E., Bradbury, P., 2017. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Res. 19, 54. https://doi.org/10.1186/s13058-017-0836-3

Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T., Lin, C.-Y., 2014. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8, S11. https://doi.org/10.1186/1752-0509-8-S4-S11

Clark, A.J., Lillard, J.W., 2024. A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology. Genes 15, 1036. https://doi.org/10.3390/genes15081036

Clough, E., Barrett, T., 2016. The Gene Expression Omnibus Database, in: Mathé, E., Davis, S. (Eds.), Statistical Genomics, Methods in Molecular Biology. Springer New York, New York, NY, pp. 93–110. https://doi.org/10.1007/978-1-4939-3578-9_5

D'Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., Bianco, R., 2015. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat. Rev. 41, 877–883. https://doi.org/10.1016/j.ctrv.2015.08.001

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Diaz, J.E., Ahsen, M.E., Schaffter, T., Chen, X., Realubit, R.B., Karan, C., Califano, A., Losic, B., Stolovitzky, G., 2020. The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies. eLife 9, e52707. https://doi.org/10.7554/eLife.52707

Duarte, D., Vale, N., 2022. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discov. 3, 100110. https://doi.org/10.1016/j.crphar.2022.100110

Edge, S.B., American Joint Committee on Cancer (Eds.), 2010. AJCC cancer staging manual, 7th ed. ed. Springer, New York, NY.

Eichhorn, P.J.A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R.L., Valero, V., Seoane, J., Bernards, R., Baselga, J., 2008. Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Res. 68, 9221–9230. https://doi.org/10.1158/0008-5472.CAN-08-1740

Eustace, A.J., Conlon, N.T., McDermott, M.S.J., Browne, B.C., O'Leary, P., Holmes, F.A., Espina, V., Liotta, L.A., O'Shaughnessy, J., Gallagher, C., O'Driscoll, L., Rani, S., Madden, S.F., O'Brien, N.A., Ginther, C., Slamon, D., Walsh, N., Gallagher, W.M., Zagozdzon, R., Watson, W.R., O'Donovan, N., Crown, J., 2018. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer 18, 965. https://doi.org/10.1186/s12885-018-4852-1

Figueroa-Magalhães, M.C., Jelovac, D., Connolly, R.M., Wolff, A.C., 2014. Treatment of HER2-positive breast cancer. The Breast 23, 128–136. https://doi.org/10.1016/j.breast.2013.11.011

Fox, M., Mott, H.R., Owen, D., 2020. Class IA PI3K regulatory subunits: p110-independent roles and structures. Biochem. Soc. Trans. 48, 1397–1417. https://doi.org/10.1042/BST20190845

Gadgeel, S.M., Lew, D.L., Synold, T.W., LoRusso, P., Chung, V., Christensen, S.D., Smith, D.C., Kingsbury, L., Hoering, A., Kurzrock, R., 2013. Phase I

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother. Pharmacol. 72, 1089–1096. https://doi.org/10.1007/s00280-013-2297-4

Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., Schultz, N., 2013. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci. Signal. 6. https://doi.org/10.1126/scisignal.2004088

Garrett, J.T., Olivares, M.G., Rinehart, C., Granja-Ingram, N.D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R.S., Pao, W., McKinely, E., Manning, H.C., Chang, J., Arteaga, C.L., 2011. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. 108, 5021–5026. https://doi.org/10.1073/pnas.1016140108

Gautama, W., 2022. Breast Cancer in Indonesia in 2022: 30 Years of Marching in Place. Indones. J. Cancer 16, 1. https://doi.org/10.33371/ijoc.v16i1.920

Giaquinto, A.N., Sung, H., Newman, L.A., Freedman, R.A., Smith, R.A., Star, J., Jemal, A., Siegel, R.L., 2024. Breast cancer statistics 2024. CA. Cancer J. Clin. 74, 477–495. https://doi.org/10.3322/caac.21863

Győrffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725–731. https://doi.org/10.1007/s10549-009-0674-9

He, Y., Sun, M.M., Zhang, G.G., Yang, J., Chen, K.S., Xu, W.W., Li, B., 2021. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6, 425. https://doi.org/10.1038/s41392-021-00828-5

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Hermawan, A., Ikawati, M., Jenie, R.I., Khumaira, A., Putri, H., Nurhayati, I.P., Angraini, S.M., Muflikhasari, H.A., 2021. Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. Saudi Pharm. J. 29, 12–26. https://doi.org/10.1016/j.jsps.2020.12.002

Hermawan, A., Putri, H., Utomo, R.Y., 2020. Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. Mol. Divers. 24, 933–947. https://doi.org/10.1007/s11030-019-10003-2

Hermawan, A., Ucche, S., Ibadurrahman, W., Ardi, K.P., Djerico, C., 2024. Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development, in: Rezaei, N. (Ed.), Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach, Interdisciplinary Cancer Research. Springer Nature Switzerland, Cham, pp. 377–431. https://doi.org/10.1007/16833_2024_246

Hsu, P., Tian, B., Yang, Y., Wang, Y., Liu, S., Urisman, A., Yang, C., Xu, Z., Jablons, D., You, L., 2019. Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. Oncol. Rep. https://doi.org/10.3892/or.2019.7207

Ignatov, A., Eggemann, H., Burger, E., Ignatov, T., 2018. Patterns of breast cancer relapse in accordance to biological subtype. J. Cancer Res. Clin. Oncol. 144, 1347–1355. https://doi.org/10.1007/s00432-018-2644-2

Iqbal, Nida, Iqbal, Naveed, 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int. 2014, 1–9. https://doi.org/10.1155/2014/852748

Jodynis-Liebert, J., Kujawska, M., 2020. Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence. J. Clin. Med. 9, 718. https://doi.org/10.3390/jcm9030718

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Kaczyńska, A., Herman-Antosiewicz, A., 2017. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells. Breast Cancer 24, 271–280. https://doi.org/10.1007/s12282-016-0700-9

Kanehisa Laboratories, 2020. KEGG PATHWAY: Pathways in cancer - Homo sapiens (human) [WWW Document]. KEGG Pathw. URL https://www.kegg.jp/pathway/hsa05200 (accessed 7.13.26).

Kanehisa Laboratories, 2016. KEGG PATHWAY: EGFR tyrosine kinase inhibitor resistance - Reference pathway [WWW Document]. URL https://www.kegg.jp/pathway/map01521 (accessed 7.29.26).

Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., Ishiguro-Watanabe, M., 2023. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587–D592. https://doi.org/10.1093/nar/gkac963

Khatoon, E., Banik, K., Harsha, C., Sailo, B.L., Thakur, K.K., Khwairakpam, A.D., Vikkurthi, R., Devi, T.B., Gupta, S.C., Kunnumakkara, A.B., 2022. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin. Cancer Biol. 80, 306–339. https://doi.org/10.1016/j.semcancer.2020.06.014

Kim, H.J., Eom, Y.H., Choi, S.H., 2023. Prognostic influences of B-cell lymphoma 2–positive expression on late recurrence in breast cancer. Ann. Surg. Treat. Res. 105, 20–30. https://doi.org/10.4174/astr.2023.105.1.20

Konecny, G.E., Pegram, M.D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D.W., Spehar, G., Mullin, R.J., Keith, B.R., Gilmer, T.M., Berger, M., Podratz, K.C., Slamon, D.J., 2006. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Res. 66, 1630–1639. https://doi.org/10.1158/0008-5472.CAN-05-1182

Kong, Y., Chen, J., Zhou, Z., Xia, H., Qiu, M.-H., Chen, C., 2014. Cucurbitacin E Induces Cell Cycle G2/M Phase Arrest and Apoptosis in Triple Negative Breast Cancer. PLoS ONE 9, e103760. https://doi.org/10.1371/journal.pone.0103760

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Kuhn, M., Von Mering, C., Campillos, M., Jensen, L.J., Bork, P., 2007. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 36, D684–D688. https://doi.org/10.1093/nar/gkm795

Lan, T., Wang, L., Xu, Q., Liu, W., Jin, H., Mao, W., Wang, Xian, Wang, Xiaojia, 2013. Growth inhibitory effect of Cucurbitacin E on breast cancer cells Vol. 6, Issue 9.

Lee, A.V., Oesterreich, S., Davidson, N.E., 2015. MCF-7 Cells—Changing the Course of Breast Cancer Research and Care for 45 Years | JNCI: Journal of the National Cancer Institute | Oxford Academic [WWW Document]. URL https://academic.oup.com/jnci/article-abstract/107/7/djv073/912073?redirectedFrom=fulltext#no-access-message (accessed 7.13.26).

Liao, Y., Wang, J., Jaehnig, E.J., Shi, Z., Zhang, B., 2019. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199–W205. https://doi.org/10.1093/nar/gkz401

Lin, S., Chang, C., Hsu, C., Tsai, M., Cheng, H., Leong, M.K., Sung, P., Chen, J., Weng, C., 2020. Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. Br. J. Pharmacol. 177, 1409–1423. https://doi.org/10.1111/bph.14816

Liu, Y., Yang, H., Guo, Q., Liu, T., Jiang, Y., Zhao, M., Zeng, K., Tu, P., 2020. Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways. Molecules 25, 560. https://doi.org/10.3390/molecules25030560

Luo, J., Zou, H., Guo, Y., Tong, T., Ye, L., Zhu, C., Deng, L., Wang, B., Pan, Y., Li, P., 2022. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res. 24, 99. https://doi.org/10.1186/s13058-022-01596-y

Manning, B.D., Toker, A., 2017. AKT/PKB Signaling: Navigating the Network. Cell 169, 381–405. https://doi.org/10.1016/j.cell.2017.04.001

Marostica, L.L., Silva, I.T., Kratz, J.M., Persich, L., Geller, F.C., Lang, K.L., Caro, M.S.B., Durán, F.J., Schenkel, E.P., Simões, C.M.O., 2015. Synergistic

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Antiproliferative Effects of a New Cucurbitacin B Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549. Chem. Res. Toxicol. 28, 1949–1960. https://doi.org/10.1021/acs.chemrestox.5b00153

Nurhayati, I.P., Khumaira, A., Ilmawati, G.P.N., Meiyanto, E., Hermawan, A., 2020. Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells. Asian Pac. J. Cancer Prev. 21, 1259–1267. https://doi.org/10.31557/APJCP.2020.21.5.1259

Orrantia-Borunda, E., Acuña-Aguilar, L.E., Ramírez-Valdespino, C.A., 2022. Nanomaterials for Breast Cancer, in: Mayrovitz, H.N. (Ed.), Breast Cancer. Exon Publications, Brisbane (AU).

Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., Li, X., 2024. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. Medicine (Baltimore) 103, e38508. https://doi.org/10.1097/MD.0000000000038508

Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z.-L., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D.-L., Han, Y.-F., Fong, W.-F., Ko, K.-M., 2013. New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. Evid. Based Complement. Alternat. Med. 2013, 1–25. https://doi.org/10.1155/2013/627375

Parsons, S.J., Parsons, J.T., 2004. Src family kinases, key regulators of signal transduction. Oncogene 23, 7906–7909. https://doi.org/10.1038/sj.onc.1208160

Pawlus, M., Wang, L., Hu, C.-J., 2014. STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 33, 1670–1679. https://doi.org/10.1038/onc.2013.115

Putra, I.M.R., Lestari, I.A., Fatimah, N., Hanif, N., Ujiantari, N.S.O., Putri, D.D.P., Hermawan, A., 2024. Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells. Comput. Biol. Chem. 111, 108084. https://doi.org/10.1016/j.compbiolchem.2024.108084

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Rajendran, V., Jain, M.V., 2018. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells. Methods Mol. Biol. 1692, 89–95. https://doi.org/10.1007/978-1-4939-7401-6_8

Rexer, B.N., Arteaga, C.L., 2012. Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications. Crit. Rev. Oncog. 17, 1–16. https://doi.org/10.1615/CritRevOncog.v17.i1.20

Riss, T.L., Moravec, R.A., Niles, A.L., Benink, H.A., Worzella, T.J., Minor, L., 2013. Cell Viability Assays.

Ruiz-Saenz, A., Dreyer, C., Campbell, M.R., Steri, V., Gulizia, N., Moasser, M.M., 2018. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 78, 3645–3658. https://doi.org/10.1158/0008-5472.CAN-18-0430

Saeed, M.E.M., Boulos, J.C., Elhaboub, G., Rigano, D., Saab, A., Loizzo, M.R., Hassan, L.E.A., Sugimoto, Y., Piacente, S., Tundis, R., Yagi, S., Khalid, H., Efferth, T., 2019. Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells. Phytomedicine 62, 152945. https://doi.org/10.1016/j.phymed.2019.152945

Saxena, A.R., Ilic, Z., Sripada, V., Crawford, D.R., 2020. Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition. Nutr. Res. 78, 93–104. https://doi.org/10.1016/j.nutres.2020.05.007

Sayers, E.W., Bolton, E.E., Brister, J.R., Canese, K., Chan, J., Comeau, D.C., Connor, R., Funk, K., Kelly, C., Kim, S., Madej, T., Marchler-Bauer, A., Lanczycki, C., Lathrop, S., Lu, Z., Thibaud-Nissen, F., Murphy, T., Phan, L., Skripchenko, Y., Tse, T., Wang, J., Williams, R., Trawick, B.W., Pruitt, K.D., Sherry, S.T., 2022. Database resources of the national center for biotechnology information. Nucleic Acids Res. 50, D20–D26. https://doi.org/10.1093/nar/gkab1112

SEER Cancer Stat Facts: Female Breast Cancer. Surveillance, Epidemiology, and End Results Program. Data for five-year relative survival: SEER 21,

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

excluding Illinois, 2016–2022. [WWW Document], n.d. . SEER. URL https://seer.cancer.gov/statfacts/html/breast.html (accessed 7.28.26).

Semenza, G.L., 2012. Hypoxia-inducible factors in physiology and medicine - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/22304911/ (accessed 7.12.26).

Sharma, J.D., Khanna, S., Ramchandani, S., Kakoti, L.M., Baruah, A., Mamidala, V., 2021. Prevalence of Molecular Subtypes of Breast Carcinoma and Its Comparison between Two Different Age Groups: A Retrospective Study from a Tertiary Care Center of Northeast India. South Asian J. Cancer 10, 220–224. https://doi.org/10.1055/s-0041-1731905

Si, W., Lyu, J., Liu, Z., Wang, C., Huang, J., Jiang, L., Ma, T., 2019. Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation. J. Cancer 10, 5843–5851. https://doi.org/10.7150/jca.31303

Siddiqa, A., Long, L.M., Li, L., Marciniak, R.A., Kazhdan, I., 2008. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 8, 129. https://doi.org/10.1186/1471-2407-8-129

Sleightholm, R., Neilsen, B.K., Elkhatib, S., Flores, L., Dukkipati, S., Zhao, R., Choudhury, S., Gardner, B., Carmichael, J., Smith, L., Bennion, N., Wahl, A., Baine, M., 2021. Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study. J. Clin. Med. Res. 13, 9–19. https://doi.org/10.14740/jocmr4398

Sörensen, P.M., Iacob, R.E., Fritzsche, M., Engen, J.R., Brieher, W.M., Charras, G., Eggert, U.S., 2012. The natural product cucurbitacin E inhibits depolymerization of actin filaments. ACS Chem. Biol. 7, 1502–1508. https://doi.org/10.1021/cb300254s

Sun, C., Zhang, M., Shan, X., Zhou, X., Yang, J., Wang, Y., Li-Ling, J., Deng, Y., 2010. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

via STAT3 signaling. J. Cancer Res. Clin. Oncol. 136, 603–610. https://doi.org/10.1007/s00432-009-0698-x

Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A.L., Fang, T., Doncheva, N.T., Pyysalo, S., Bork, P., Jensen, L.J., von Mering, C., 2023. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646. https://doi.org/10.1093/nar/gkac1000

Trepel, J., Mollapour, M., Giaccone, G., Neckers, L., 2010. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–549. https://doi.org/10.1038/nrc2887

Üremiş, M.M., Üremiş, N., Türköz, Y., 2023. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways. Steroids 198, 109261. https://doi.org/10.1016/j.steroids.2023.109261

Van Meerloo, J., Kaspers, G.J.L., Cloos, J., 2011. Cell Sensitivity Assays: The MTT Assay, in: Cree, I.A. (Ed.), Cancer Cell Culture, Methods in Molecular Biology. Humana Press, Totowa, NJ, pp. 237–245. https://doi.org/10.1007/978-1-61779-080-5_20

Vazquez-Martin, A., Oliveras-Ferraros, C., Colomer, R., Brunet, J., Menendez, J.A., 2008. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 19, 1097–1109. https://doi.org/10.1093/annonc/mdm589

Vinod, B.S., Nair, H.H., Vijayakurup, V., Shabna, A., Shah, S., Krishna, A., Pillai, K.S., Thankachan, S., Anto, R.J., 2015. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis. Cell Death Discov. 1, 15061. https://doi.org/10.1038/cddiscovery.2015.61

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Vivekanandhan, S., Knutson, K.L., 2022. Resistance to Trastuzumab. Cancers 14, 5115. https://doi.org/10.3390/cancers14205115

Wang, L., Xu, H., Li, X., Chen, H., Zhang, Haigang, Zhu, X., Lin, Z., Guo, S., Bao, Z., Rui, H., He, W., Zhang, Hui, 2023. Cucurbitacin E reduces IL-1β-induced inflammation and cartilage degeneration by inhibiting the PI3K/Akt pathway in osteoarthritic chondrocytes. J. Transl. Med. 21, 880. https://doi.org/10.1186/s12967-023-04771-7

Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z., Wang, B., Shao, Z., Wang, Z., Hu, X., 2011. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11, 248. https://doi.org/10.1186/1471-2407-11-248

Wang, W., He, Y.-F., Sun, Q.-K., Wang, Y., Han, X.-H., Peng, D.-F., Yao, Y.-W., Ji, C.-S., Hu, B., 2014. Hypoxia-inducible factor 1α in breast cancer prognosis. Clin. Chim. Acta Int. J. Clin. Chem. 428, 32–37. https://doi.org/10.1016/j.cca.2013.10.018

Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R.M., Fu, X., Botero, M.F., Healy, N.A., Hilsenbeck, S.G., Phillips, G.L., Chamness, G.C., Rimawi, M.F., Osborne, C.K., Schiff, R., 2011. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation. Breast Cancer Res. BCR 13, R121. https://doi.org/10.1186/bcr3067

Wee, P., Wang, Z., 2017. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 9, 52. https://doi.org/10.3390/cancers9050052

Wei, F., Zhang, Y., Geng, L., Zhanng, P., Wang, G., Liu, Y., 2015. mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer [WWW Document]. URL https://www.mdpi.com/1422-0067/16/2/3267 (accessed 7.13.26).

Wisinski, K.B., Tevaarwerk, A.J., Burkard, M.E., Rampurwala, M., Eickhoff, J., Bell, M.C., Kolesar, J.M., Flynn, C., Liu, G., 2016. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin.

UNIVERSITAS
GADJAH MADA
Bioinformatics and In Vitro Evaluation of The Potential of Cucurbitacin E as a Chemosensitizer in MCF-7/HER2 Cells
Inas Haidar, Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc.; Prof. Dr. rer. nat. apt. Adam Hermawan, S.farm M.S
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Cancer Res. 22, 2659–2667. https://doi.org/10.1158/1078-0432.CCR-15-2365

Xia, X., 2017. Bioinformatics and Drug Discovery. Curr. Top. Med. Chem. 17, 1709–1726. https://doi.org/10.2174/1568026617666161116143440

Ye, M., Huang, W., Liu, R., Kong, Y., Liu, Y., Chen, X., Xu, J., 2021. Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. Front. Pharmacol. 12, 651516. https://doi.org/10.3389/fphar.2021.651516

Yu, H., Lee, H., Herrmann, A., Buettner, R., Jove, R., 2014. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736–746. https://doi.org/10.1038/nrc3818

Zhang, R., Qiao, H., Chen, S., Chen, X., Dou, K., Wei, L., Zhang, J., 2016. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biol. Ther. 17, 925–934. https://doi.org/10.1080/15384047.2016.1210728

Zhang, T., Li, J., Dong, Y., Zhai, D., Lai, L., Dai, F., Deng, H., Chen, Y., Liu, M., Yi, Z., 2012. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res. Treat. 135, 445–458. https://doi.org/10.1007/s10549-012-2175-5

Zhao, Z., Mu, H., Li, Y., Liu, Y., Zou, J., Zhu, Y., 2020. Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients. Clin. Transl. Oncol. 22, 1892–1906. https://doi.org/10.1007/s12094-020-02332-8